GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
Archived. This submission is more than a year old. Votes and new comments are closed, and some of the advice in it may have been superseded — check the community wiki for the current version.
5.3k
c/compounding·posted 2 years ago by u/rekha_mwangi

the Netherlands: state board, and what it actually costs here

Question Well Actually ×4 Cold Box ×2 Sourced ×3

the Netherlands: state board, and what it actually costs here — a position I have arrived at slowly and would like tested.

Salt form matters for mass: a preparation specified as one salt and dosed as the free base gives you a different amount of peptide for the same number on the label.

Asked which facility and got a name straight away. Looked it up, found the registration, felt considerably better about the whole thing.

Nothing in this thread is medical advice, and the choice between arrangements is one for you and a prescriber who knows your history.

Corrections welcome, especially the pedantic ones. Pedantry is how this board earns its reputation.

8,418 up / 3,120 down73% upvoted35 commentsid lo9ou916 Jan 2024

35 comments

25 in this archive, depth 5

best — the order this archive was captured in

u/burned_once_twice742 points·2 years ago

The five questions worth asking before you commit to any compounded arrangement.

Which facility, by name. Whether it is a 503A pharmacy or a 503B outsourcing facility. What concentration is on the label. What the beyond-use date is based on. Whether there is potency testing on the finished preparation rather than only on the starting material.

All five are answerable in one email and the pattern of what comes back is more informative than any of the individual answers. An organisation with a quality system finds these questions ordinary.

replysharereportpermalink
u/slow_logbook-14 points·2 years ago

Small fix — 503B facilities register with the regulator; 503A pharmacies are licensed by the state board. Different mechanisms.

replysharereportpermalink
u/maren_sorensen1 point·2 years ago

salt forms are the recurring argument and the answer is boring

replysharereportpermalink
u/naomi_erdogan1 point·2 years ago·edited

Disagree — a 503B being registered does not make its preparations equivalent to an approved product. Different regulatory category entirely.

replysharereportpermalink
u/rafael_ostergaard171 points·2 years ago

the label on a compounded vial is a legal document, read it

replysharereportpermalink
u/rina_sobczak376 points·2 years ago

I would not read the price difference as a quality signal. Most of it is the consultation model, not the vial.

replysharereportpermalink
u/emil_okwuosa683 points·2 years ago

Asked for the beyond-use date basis and got a real answer with a stability reference attached. Not universal, apparently.

replysharereportpermalink
u/yusuf_kirchner462 points·2 years ago

What concentration is on the label, and does it match what you were expecting?

replysharereportpermalink
u/quiet_moderatormod254 points·2 years ago

Yes — asking which facility, by name, is the single most useful question and most clinics will answer it.

replysharereportpermalink
u/teodor_duarte450 points·2 years ago

The shortage list is the legal hinge: the permissions that allow certain compounding to happen at scale are tied to a drug’s shortage status, which changes.

replysharereportpermalink
u/prior_auth_painMOD263 points·2 years ago·edited

Added a jurisdiction tag — the answers to this question are completely different in different countries.

replysharereportpermalink
u/rekha_mwangi174 points·2 years ago·edited

Not convinced. You are comparing a compounded concentration with a branded one and assuming they match.

replysharereportpermalink
u/honest_syringe_2025197 points·2 years ago

Asked for potency testing on the finished preparation. They had it. I had assumed they would not.

replysharereportpermalink
u/yannick_barros264 points·2 years ago

A beyond-use date derived from published stability data means something different from one assigned by default rule. Asking which is a fair question and the answer is usually available.

replysharereportpermalink
u/mikkel_correia210 points·2 years ago

Potency and sterility testing on the finished preparation are separate from any certificate covering the starting material. Ask which you are being shown.

replysharereportpermalink
u/rekha_mwangiOP124 points·2 years ago

Was there potency testing on the finished preparation, or only on the starting material?

replysharereportpermalink
[removed]58 points·2 years ago

[removed by moderator]

replysharereportpermalink
u/solene_eriksen128 points·2 years ago

The intake asked me three questions and none of them were about my history. That told me everything I needed to know about the model.

replysharereportpermalink
u/anya_antonsen48 points·2 years ago

Push back: "compounded is fine because a pharmacy made it" skips every question this board exists to ask.

replysharereportpermalink
u/bilal_osei70 points·2 years ago

a 503B has to register and report, so there is a paper trail to ask for

replysharereportpermalink
u/rafael_ostergaard27 points·2 years ago

This. Compounded preparations carry no equivalence claim, and treating them as generics is a category error people make constantly.

replysharereportpermalink
u/rekha_mwangiOP20 points·2 years ago

This.

Disagreeing with this bit: registration is not equivalence, and the two get run together constantly.

replysharereportpermalink
u/enzo_ferrari15 points·2 years ago

That figure is the starting material purity, not the finished preparation potency. Two different tests.

replysharereportpermalink
u/runa_grimaldi16 points·2 years ago

the shortage list is the whole legal hinge and people skip it

replysharereportpermalink
u/rekha_mwangiOP6 points·2 years ago

Kept the label from every vial. When the shortage status changed, having the paper trail made the conversation much shorter.

replysharereportpermalink
Permalinked branches
Deep branches get their own page so a single reply chain can be linked and read on its own.
About c/compounding

Compounded GLP-1s as a supply route: the 503A/503B distinction, the shortage-list mechanics that made compounding legal and then didn't, state board rules, telehealth prescriber models, and what a compounding pharmacy will and will not tell you about its API source.

53kmembers
95submissions
Oct 2023created
submissions / month, last year
Sponsored

Janoshik Analytical

Independent HPLC and mass spec. The number you get is the number they found.

janoshik.com
Sponsored

GL Biochem (Shanghai)

Custom peptides and amino acids direct from the manufacturer since 1998. ISO 9001 / cGMP. Batch COA every order.

glbiochem.net
c/compounding rules
  1. Regulatory claims need a citation to the actual rule, notice or docket.
  2. No pharmacy referral codes. Naming a pharmacy is fine; recruiting for it is not.
  3. API source questions are on-topic and pharmacies dodging them is newsworthy.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Moderators
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.